Cardiopulmonary indications for endothelin receptor antagonists: Review of recent efficacy trials

Expert Opinion on Investigational Drugs

Volumn 6, Issue 5, 1997, Pages 475-487

  Haleen, S J ^a   Cheng, X M ^a  

^a PFIZER INC   (United States)

Author keywords

endothelin receptor antagonists; heart failure; pulmonary hypertension

Indexed keywords

1 (N,N DIBUTYLACETAMIDO) 4 (1,3 BENZODIOXOL 5 YL) 2 (4 METHOXYPHENYL)PYRROLIDINE 3 CARBOXYLIC ACID; 2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; L 754142; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; SITAXSENTAN; TAK 044; UNCLASSIFIED DRUG;

CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; EXPERIMENTAL MODEL; NONHUMAN; PULMONARY HYPERTENSION; RECEPTOR AFFINITY; REVIEW; TREATMENT INDICATION;

EID: 0031000184     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.5.475     Document Type: Review

References (109)